According to Kim Lee at RDEA's "Study 111" demonstrated reduction of serum uric acid levels below 4mg/dL in 100% of patients when RDEA 594 was used in combination with Allopurinol at the highest dose tested.
The data was disclosed at the recent ACR meeting where SVNT presented additional OLE data on "K."
In several large studies both Allop and Febux had about 2% of patients allergic to the drug. These patients will likely never be able to go on the combo treatment w/RDEA. Again,like the HIV/AIDS mkt,the gout mkt is so big and growing there will be ample patients for all entrants to make good money. Patients respond differently to all drugs. SVNT only has to capture 1% of the total world gout mkt(10M patients ?)....100k TFG patients.....to make meaningful revs and profits @ $20k/yr/pp or higher. That has always been the play and nothing will change that until we see another gout drug drop uric acid levels to under 1 in 24 hours like K does. K is the tophi buster and as Decision Resources' 90 surveyed rheumatolopgists said, will be the "gold standard" in gout by 2013-2018.
Obviously I'm not a doctor, not in the field nore a patient but is this latest RDEA study findings valid enough to take the wind from SVNT's K sails for good? And does anyone here think this might be the biggest reason SVNT has dropped so much and staying down now?